Chemomab Therapeutics Ltd.
CMMB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534248
In the last 90 days, Chemomab Therapeutics Ltd. insiders filed 0 open-market purchases and 1 sale; 13 institutions reported holding it in 13F filings for Q2 2026, worth $615.3K in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Chemomab Therapeutics Ltd. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 11 | 16 | +5 |
| Shares | 2.53M | 2.81M | +283.2K (+11.2%) |
| Value | $2.26M | $1.43M | −$830.0K (−36.6%) |
New holders (7)
Institutions that held Chemomab Therapeutics Ltd. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Morgan Stanley | 70,915 | $36.2K | 0.00% |
| Two Sigma Investments, LP | 56,305 | $28.7K | 0.00% |
| Two Sigma Advisers, LP | 35,400 | $18.1K | 0.00% |
| Citadel Advisors LLC | 32,677 | $16.7K | 0.00% |
| XTX Topco Ltd | 29,047 | $14.8K | 0.00% |
| Virtu Financial LLC | 25,808 | $13.0K | 0.00% |
| Millennium Management LLC | 19,701 | $10.0K | 0.00% |
Sold out (2)
Institutions that held Chemomab Therapeutics Ltd. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Newbridge Financial Services Group, Inc. | 1,100 | $985 |
| UBS Group AG | 141 | $126 |